Market Overview

Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated

Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s earnings report brought mostly bad news for investors, which resulted in an 18-percent plunge in the stock Thursday morning.

But not all analysts are ready to throw in the towel, as Credit Suisse's Vamil Divan maintains an Outperform rating on Teva with an unchanged $39 price target.

Teva's report consisted of an earnings miss, a reduced guidance and a dividend cut, but there were some positive aspects to the quarter for the Israel-based company, Divan noted. Specifically, the Specialty Medicines business came in better than expected due to Copaxone and Treanda/Bendeka and this won't "attract much attention today."

Needless to say the negatives outweigh the positives, including the absence of any update relating to the vacant CEO and CFO positions, the analyst said. In fact, until these two positions are filled it will be "difficult" for investors to become more constructive on the company's longer-term outlook.

Teva faced notable challenges in the U.S. market where its Generics Medicine business fell short of expectations by $89 million due to greater generic price erosion and lower volumes. If it's of any relief to investors, some of the other negative aspects of the report, including a dividend reduction, were widely expected.

Related Links:

Analyst Wonders If AstraZeneca's CEO Would Be A Fit At Teva

States Are Firing Back At Opioid Drug Producers

Latest Ratings for TEVA

Jul 2019DowngradesEqual-WeightUnderweight
Jul 2019AssumesNeutral
Jun 2019Initiates Coverage OnUnderweight

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Copaxone Generic drugs israel Pharmaceutical Vamil DivanAnalyst Color Reiteration Analyst Ratings Best of Benzinga


Related Articles (TEVA)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Goldman Sachs Raises Tesla's Price Target A Month After Cutting It, Still Remains Bearish

As Netflix Tackles Suicidal Issues, Hospital Psych Units Grapple With Real-Life Consequences